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Background: Transrectal ultrasound-guided prostate biopsies (TRUSBx), in spite of being one of the
most frequently performed urological ofﬁce procedures, are associated with a spectrum of complications,
most signiﬁcantly including infection. The aim of the study is to evaluate the prevalence of
ﬂuoroquinolone-resistant bacteria in rectal swabs from our local population prior to TRUSBx and to
identify risk factors among a patient population harboring ﬂuoroquinolone-resistant organisms.
Methods: We prospectively included 541 men who were submitted for TRUSBx in our center from
March 2011 to June 2015. The indications for TRUSBx were an elevated prostate-speciﬁc antigen level
and/or abnormal digital rectal exam. All patients were randomly divided into two groups: Group 1
(n ¼ 279 cases) who received standard empirical prophylactic antibiotics and Group 2 who received
targeted prophylaxis based on a rectal swab culture and susceptibility result. Differences in risk factors
between quinolone-resistant and nonresistant patients were compared. Univariate and multivariate
analyses were performed to identify independent potential risk factors associated with ﬂuoroquinolone-
resistant rectal ﬂora.
Results: Sixteen out of 271 men developed infectious complications after TRUSBx in the group receiving
standard empirical prophylaxis (5.7%). No men in the group who received targeted prophylactic anti-
biotic guided by rectal swab developed infectious complications. Among the 262 patients who under-
went prebiopsy rectal swab cultures, 76 men (29%) displayed ﬂuoroquinolone-resistant rectal ﬂora (29%).
In the multivariate analysis, a history of antibiotic exposure before prostate biopsy was the only inde-
pendent factor associated with an increased risk of ﬂuoroquinolone resistance.
Conclusion: Determining the prevalence of ﬂuoroquinolone resistance in rectal ﬂora has important
implications in the selection of targeted prophylactic antibiotic regimens. Antimicrobial proﬁles guided
by rectal swabs may prove useful to optimize prophylaxis prior to TRUSBx; this strategy is effective at
reducing the rates of infectious complications, including sepsis, especially in men at higher risk of in-
fectious complications.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Transrectal ultrasound-guided prostate biopsies (TRUSBx), in
spite of being a frequently performed urological procedure, are
associated with a spectrum of complications, most signiﬁcantly
including infection, which affects up to 5% of patients.1 In the most
severe cases, infection leads to sepsis, which poses signiﬁcantlexandria University, 41 St.
hmy).
ciﬁc Prostate Society, Published bmorbidity to patients with inpatient hospital stays, intensive care
requirements, and even death. Escherichia coli is the pathogenmost
commonly associated with infections after TRUSBx.2e4
Antibiotic prophylaxis with ﬂuoroquinolones (FQ) is currently
used on a regular routine basis for preventing sepsis after TRUSBx
because of its broad spectrum activity against gram-positive and
gram-negative organisms and the convenience of using an oral
agent with a high sustained concentration in urine and prostate
tissue;5e7 however, there is growing evidence that the infection
rate after TRUSBx is on the rise and it continues to be a problem,
frequently caused by an increasing prevalence of FQ-resistant
organisms.8e12y Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 4 (2016) 113e117114In an attempt to reduce the rate of infectious complications,
there are an increasing number of publications citing different
prophylaxis regimens.13e15 The aim of this study is to evaluate
the prevalence of FQ-resistant bacteria in rectal swabs from
men presented to the outpatient department at Alexandria
University Hospital, Egypt, prior to TRUSBx and to identify the
risk factors among a patient population harboring FQ-resistant
organisms.2. Materials and methods
We prospectively included 541 men who were submitted for
TRUSBx in our center from March 2011 to June 2015. All patients
were randomly divided into two groups: Group 1 (n ¼ 279 cases)
who received standard empirical prophylactic antibiotic with oral
ciproﬂoxacin 500 mg and metronidazole 500 mg at least 1 hour
before biopsy and continued this twice daily for 3 days (a total of 6
doses of each antibiotic) and Group 2 who received targeted pro-
phylaxis based on a rectal swab culture and susceptibility results
performed 1 week before TRUSBx provided in a 3-day regimen on
the day before the biopsy, the day of the biopsy, and the day after
the biopsy (Fig. 1).
Sealed opaque envelopes were used as the method of random-
ization which were placed into a box and mixed. Allocation
concealment was achieved using an independent person (“biopsy
nurse”) who selected one of the sealed opaque envelopes blindly.
Thus patients were randomly allocated to Group 1 or Group 2
before the procedure. The study was approved through the Insti-
tutional Review Board.
Demographic data were obtained for all patients, as well as
diabetic status, recurrent urinary tract infections (UTI), presence of
a urinary catheter, prior FQ exposure within 6 months before the
biopsy, and past TRUS biopsies (Table 1). The results of rectal swabs
and infectious complications within 30 days of the biopsy were also
recorded. The deﬁnition of post-TRUSBx infection was distinct
clinical presentations, including fever > 38.5C, UTI, pyelonephritis,
bacteremia, prostatitis, systemic inﬂammatory response syndrome,
and sepsis. The indications for TRUS biopsies were an elevated
prostate-speciﬁc antigen level (PSA) and/or abnormal digital rectal
exam. All TRUSBx were performed at our institution in an ofﬁce-
based setting.2.1. TRUSBx technique
All patients provided informed consent before the biopsy after
they had been instructed by the physician regarding all possible
complications. Patients were strictly advised not to take nonste-
roidal anti-inﬂammatories and anticoagulant medications for a
week before the application.Cases that were submiƩed for TRUSBx
(n = 541)
Rectal swab
(Group 2; n = 262)
FQ resistant
(n = 76)
FQ sensiƟve
(n = 186)
Standard empirical  prophylaxis
(Group 1; n = 279)
Fig. 1. Study cases. FQ, ﬂuroquinolones; TRUSBx, transrectal ultrasound-guided pros-
tate biopsies.A standard prebiopsy preparation was applied for all patients.
No enema was used. Patients only fasted the night before. The bi-
opsy procedure was carried out under local periprostatic anes-
thesia. TRUS-guided biopsies were achieved through transrectal
ultrasonography using a 7-MHz probe attached. Biopsies were
carried out with the patient in the left decubital position using an
automated biopsy gun with a disposable 18-G biopsy needle.
All biopsies were carried out through a systematic approach (a
standard 12-core biopsy taken from the base, mid gland, and the
apex of the right and left sides of the lateral and far-lateral pe-
ripheral zone). Two transitional zone biopsies were added in cases
of a previous history of negative biopsies.
Patients were advised to present to the emergency department
if they developed symptoms of sepsis within 30 days of the biopsy.
All patients with sepsis, as deﬁned as fever > 38C in the pres-
ence of constitutional symptoms, were admitted for inpatient
management. Empiric treatment withmeropenem 1 g [intravenous
(i.v.)] twice daily was commenced after collecting blood and urine
for culture.
The main outcome criterion was the incidence of bacteriuria
(deﬁned as  103colony-forming units/mL) within 30 days of bi-
opsy. Secondary endpoints included the incidence of clinical
symptoms of fever, ﬂushing, chills, or any weakness on physical
examination and UTI, deﬁned as the association of leukocyturia
(>5 cells/high-power ﬁeld) and bacteriuria, or any signiﬁcant
change in the biological results suggesting an infection including a
blood cell count and C-reactive protein.2.2. Statistical analysis
Differences in risk factors between quinolone-resistant and
nonresistant patients were compared using a Fisher exact test with
statistical signiﬁcance ascribed at P < 0.05. Univariate and multi-
variate analyses were performed to identify independent potential
risk factors associated with FQ-resistant rectal ﬂora. Statistical an-
alyses were performed with SPSS version 21.0 (SPSS Inc., Chicago,
IL, USA) statistical software package.3. Results
Themean age of patients was 63.6 years and 65.2 years in Group
1 and Group 2, respectively (P ¼ 0.4).There was no difference in
mean PSA value (P ¼ 0.62) or age-adjusted Charlson comorbidity
score (P ¼ 0.25) between the two groups.
Sixteen men out of 279 men developed infectious complications
after TRUSBx in the group receiving standard empirical prophylaxis
(5.7%) in the form of fever and pyelonephritis including two cases of
sepsis. None of the two men admitted for sepsis required intensive
care treatment and all were successfully managed with i.v. ﬂuids
and i.v. meropenem (1 g twice daily). No men in the group who
received targeted prophylactic antibiotic guided by rectal swab
developed infectious complications. This result was statistically
signiﬁcant (P¼ 0.003). Culture and susceptibility results for the two
men with sepsis demonstrated FQ resistant extended-spectrum b-
lactamase-producing Escherichia coli.
Among the 262 patients who underwent prebiopsy rectal swab
cultures, 76 men (29%) displayed FQ-resistant rectal ﬂora (29%). Of
the 76 bacterial isolates, 84.2% were E. coli and 10.5% were Klebsiella
pneumonia. Antimicrobial susceptibility testing to FQ-resistant
strains obtained by rectal swab showed the highest resistance
notably to cotrimoxazole (85%), followed by cefotaxime (63%), and
the highest sensitivity shown to carbapenems (92.1%), fosomycin
(85.5%), amikacin (79%), followed by nitrofurantoin (63%), and
sulbactam/cefoperazone (42.1%; Fig. 2).
Table 1
Patients' demographics.
Variables Group 1 (n ¼ 279) Group 2 (n ¼ 262) P
Mean age (y) 63.6 65.2 0.461
Mean PSA (ng/mL) 18 22 0.624
Mean prostate volume (mL) 64 59 0.187
No. of diabetes patients 73 (26.2) 80 (30.5) 0.422
AAC (mean) 0.252
0e1 175 156
2e3 65 57
2e5 32 38
 6 7 11
Prior UTI 136 (48.7) 116 (44.3) 0.582
Presence of urinary catheter 35 (12.5) 26 (9.9) 0.182
Prior antibiotic exposure within 6 mo 90 (32.2) 87 (33.2) 0.922
Prior prostate biopsy 52 (18.6) 54 (20.6) 0.863
Data are presented as n (%).
ACC, age-adjusted Charlson comorbidity score; PSA, prostate-speciﬁc antigen; UTI, urinary tract infection.
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Fig. 2. Antimicrobial susceptibility testing to ﬂuoroquinolone-resistant strains.
Table 3
Univariate logistic regression analysis of factors inﬂuencing quinolone resistance.
FQ resistance OR (95% CI) P
Age  65 y 1.28 (0.42e4.35) 0.453
Diabetes 3.47 (0.1e6.32) 0.520
Prior UTI 4.45 (1.36e10.52) 0.02a)
Presence of urinary catheter 1.08 (0.22e6.43) 0.38
Prior antibiotic exposure within 6 mo 34.2 (3.16e178.52) 0.001a)
Prior prostate biopsy 3.02 (0.82e6.88) 0.24
a) Statistically signiﬁcant.
CI, conﬁdence interval; FQ, ﬂuoroquinolone; OR, odds ratio; URI, urinary tract
infection.
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prior prostate biopsy were not associated with FQ resistance. Prior
UTI and antibiotic exposure before prostate biopsy was associated
withquinolone resistance (P¼ 0.041 and0.001, respectively; Table 2).
In the univariate analysis, prior UTI and history of exposure to
antibiotics increased the risk of FQ resistance [odds ratio (OR), 4.45;
95% conﬁdence interval (CI), 1.36e10.52; P ¼ 0.02, and OR, 34.2 CI,
3.16e178.52; P ¼ 0.001, respectively] (Table 3).
In the multivariate analysis, a history of antibiotic exposure
before prostate biopsy was the only independent factor associated
with increased risk of FQ resistance (OR, 41.2; 95% CI, 3.16e328.46;
P ¼ 0.008; Table 4).Table 2
Risk factors and quinolone resistance status.
Variables FQ resistant (n ¼ 76) FQ sensitive (n ¼ 186) P
Age  65 (y) 12 (15.7) 30 (16.1) 0.18
Diabetes 28 (36.8) 52 (27.9) 0.62
Prior UTI 39 (51.3) 77 (41.33) 0.041a)
Presence of urinary catheter 9 (11.8) 17 (9.1) 0.52
Prior antibiotic exposure within 6 mo 45 (59.2) 42 (22.5) 0.001a)
Prior prostate biopsy 18 (23.6) 36 (19.3) 0.24
Data are presented as n (%).
a) Statistically signiﬁcant.
FQ, ﬂuoroquinolone; UTI, urinary tract infection.
Table 4
Multivariate logistic regression analysis of factors inﬂuencing quinolone resistance.
FQ resistance OR (95% CI) P
Prior UTI 1.62 (0.85e11.08) 0.659
Prior antibiotic exposure within 6 mo 41.2 (3.16e328.46) 0.008a)
a) Statistically signiﬁcant.
CI, conﬁdence interval; FQ, ﬂuoroquinolone; OR, odds ratio; URI, urinary tract
infection.
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The use of prophylactic antibiotics prior to TRUSBx reaches a
consensus; however, data to guide the optimal choice of prophy-
lactic antibiotic are currently lacking. No standard regimen for
antibiotic prophylaxis has been formulated despite the need to
optimize prophylaxis against infectious complications post-TRUSBx
being recognized a long time ago.16
Multiple strategies aimed at improving the safety and accept-
ability of prostate biopsies are the subject of ongoing research
studies. Different prophylactic regimens depending on local
microbiological proﬁles, and alternate approaches to prostate bi-
opsies, such as the transperineal approach, are considered
depending on availability.17 Rectal disinfection and washing the
biopsy needle with povidoneeiodine are other approaches used
with the aim of reducing infection complications post-TRUSBx in
some centers.18,19
The European Association of Urology guideline recommends the
use of a FQ as a ﬁrst-line agent for the prevention of infection from
transrectal prostate biopsy, with ciproﬂoxacin being superior to
oﬂoxacin.20 Our current clinical practice usually includes an
empirical oral FQ antibiotic usage of 3 days starting the day before
the procedure owing to their excellent prostatic penetration;7 these
agents also provide good coverage against the key pathogens
implicated in post-TRUSBx infectious complications.21 However, FQ
resistance has emerged as a growing problem resulting in a sig-
niﬁcant increase in infectious complications in men undergoing
TRUS biopsies.
Many reports have shown that the prevalence of FQ-resistant
E. coli in Western countries is on the rise.9,11 In the USA, FQ-
resistant bacteria were identiﬁed in 22% of samples from rectal
swab cultures before TRUSBx.22 Furthermore, in American men
who developed acute prostatitis after TRUSBx, the FQ-resistant rate
was reported to be 57.1%.23 Batura et al24 obtained rectal swabs
from 445 men undergoing TRUSBx and found a 13.3% incidence of
FQ-resistant coliforms. The present study looks at the local sus-
ceptibility for FQ in our patient population, with an incidence of FQ
resistance as high as 29% which is relatively high andmay be due to
an increase in antibiotic prescriptions in the past few years. In light
of the worldwide emergence of FQ resistance and its increasing
implication in post-TRUSBx infectious complications including
sepsis, the current recommendations for antimicrobial prophylaxis
need to be reevaluated.
Our results showed that targeted antibiotic prophylaxis guided
by a pre-TRUSBx rectal swab was dramatically effective in lowering
postbiopsy infectious complications. No men in the group who
received targeted prophylactic antibiotics guided by a rectal swab
developed an infectious complication. In contrast, men treatedwith
empirical prophylactic antibiotic regimen had a 5.7% rate of infec-
tious complications despite receiving ciproﬂoxacin and metroni-
dazole for 3 days. This rate matches the worldwide reported
incidence for infectious complication post-TRUSBx of around
2e6%.17 Two cases of sepsis had cultures of ciproﬂoxacin-resistant
E. coli, suggesting that ciproﬂoxacin resistance is a signiﬁcant
contributor to the failure of standard prophylaxis. This may beattributed to the frequent unsupervised use of these antibiotics or
inadequate dosing with subsequent development of resistance in
the rectal ﬂora, creating potentially worse problems in cases of
post-TRUS biopsy sepsis, where these drugs would have reduced
efﬁcacy as empirical treatment.
Several reports in literature have suggested that rectal swab
cultures before a biopsy may allow for an individualized and tar-
geted approach to providing prophylactic antibiotics and
decreased overall cost of care. Duplessis et al22 showed that rectal
cultures obtained before TRUSBx with the use of selective media
to identify FQ-resistant Enterobacteriaceae facilitate targeted
antibiotic prophylaxis and appear to be highly efﬁcacious in
reducing postprostatic biopsy infection rates. Taylor et al23 re-
ported no infectious complications in 112 men who received tar-
geted antimicrobial prophylaxis and this was associated with a
reduced cost of care. Our data show similar results, with no cases
of infectious complications in the group that received targeted
antibiotic prophylaxis guided by rectal swab culture, whereas 16
cases among 279 patients receiving empirical FQ prophylaxis
developed infectious complications including two cases of sepsis
(P ¼ 0.003).
Concerns regarding the practical implementation of rectal swab
collection need considering. Optimal timing of swab collection,
duration of targeted antibiotic regimen, target population, and cost
effectiveness has to be clearly established. The feasibility, and cost
effectiveness of routine rectal swabs for every patient undergoing
TRUSBx must be considered, as it represents a signiﬁcant burden
for clinical microbiology laboratories, and would incur several
additional costs (culture media, targeted antibiotics, etc.).
In a previous study comparing cost-effectiveness of targeted
versus empirical prophylaxis per 100 men undergoing TRUSBx,
Taylor et al23 showed that the total cost of managing infectious
complications in patients in the empirical group was US $13,219
including hospital admission, outpatient and emergency roomvisits,
prolonged antibiotic treatment, diagnostic imaging procedures,
laboratory tests, and professional fees. Cost-effectiveness analysis
revealed that targeted prophylaxis yielded a cost savings of US
$4,499 per post-TRUSBx infectious complication averted. Currently,
there is no conclusive evidence of the overall beneﬁt of routine
adoption of targeted prophylaxis and the burden of the additional
costs limits the widespread replacement of such an approach.
A more practical and feasible approach to optimize the use of
antimicrobial prophylaxis for TRUSBx is to consider the selective
application of rectal swabs before prostate biopsy in patients with
high risk factors and to use the standard protocol for low-risk pa-
tients. However, men at high risk for developing post-TRUSBx in-
fections are not yet well deﬁned. A number of recent studies tried to
look at these risk factors for infection post-TRUSBx.
Liss et al11 obtained rectal swabs from 136 men before TRUSBx
over a 3-month period. In 22% of patients, rectal cultures showed
quinolone-resistant E. coli, and patients with diabetes, Asian
ethnicity, and a prior history of TRUSBx were determined to be at a
higher risk for colonization with resistant organisms, although
these differences did not reach statistical signiﬁcance. In this series,
ﬁve patients (3.6%) developed post-TRUSBx fever, among which
only one had a positive rectal culture. Kanafani et al25 and Lau-
tenbach et al26 pointed out in their studies that previous use of FQ
was an independent risk factor for acquiring infections with
extended-spectrum b-lactamase-producing E. coli-producing or-
ganisms. Similar to those observations, prior UTI and history of
exposure to antibiotics increased the risk of FQ resistance by uni-
variate analysis in the present study. In the multivariate analysis, a
history of antibiotic exposure before prostate biopsy was the only
independent factor associated with increased risk of FQ resistance
(P ¼ 0.008).
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spectrum antimicrobials with extremely low resistance rates in
rectal ﬂora, eliminating the need for rectal culture has also been
suggested.12,14 However, the high cost and frequent use of these
antibiotics again may lead to the subsequent development of
resistance in rectal microbiota, potentially limiting its use in pro-
phylaxis prior to TRUSBx. Our patients' antimicrobial susceptibility
testing showed the highest sensitivity to cabapenems, fosomycin,
and amikacin.
The present study raises awareness of local susceptibility for FQ
in our patient population and highlights the utility of a rectal swab
as an approach to optimize antibiotic prophylaxis prior to TRUSBx
in high-risk patients. Thus a beneﬁt of screening prior to TRUSBx
and targeted prophylaxis should be considered as a thoughtful,
predictable alternative to routine empirical prophylaxis. Using a
risk stratiﬁcation approach seems to be effective at identifying
those men at higher risk of infectious complications. Future studies
will need to evaluate the cost effectiveness and clinical utility of a
prebiopsy rectal culture in targeting antibiotic prophylaxis.
We acknowledge several limitations of the present study. Firstly,
there might be a recall bias, relying on patient recall for past his-
tories of UTI and antibiotic use. Similarly, the frequency of exposure
to FQ and the duration preceding TRUSBx could not be ascertained,
therefore it is possible that some patients might have forgotten
these past events which may have led to an underestimation of the
total number of patients with a history of antibiotic use. Secondly, a
true cost-beneﬁt analysis between routine empirical antibiotic
prophylaxis and targeted antibiotic prophylaxis has not been
formally undertaken in our study. Finally, lack of culture stan-
dardization in microbiological laboratories may represent a
limiting factor.
In conclusion, determining the prevalence of FQ resistance in
rectal ﬂora has important implications in the selection of targeted
prophylactic antibiotic regimens. Antimicrobial proﬁles guided by
rectal swabs may prove useful to optimize prophylaxis prior to
TRUSBx; this strategy is effective at reducing the rates of infectious
complications, including sepsis, especially in men at higher risk for
infectious complications.Conﬂicts of interest
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